The first practical point-of-care screening solution for diabetic retinopathy
How it works
Image
A single image per eye is obtained using an indicated camera
Analyze
Images are analyzed by the AI
Result
Diagnostic result returned in under a minute
_edited.png)
3
2
1
Benefits of Point-of-Care Screening
Practical
Requires only one image per eye; rarely requires dilation
Accurate
Best-in-class efficacy proven in a pivotal prospective FDA study
Simple to operate
Can be operated by primary care personnel with no prior experience
.png)
Reimbursable
Dedicated CPT code 92229
Closes Care Gaps
Closes the diabetic eye exam care gap for HEDIS/Star quality measures
_edited.png)
_edited.png)
Regulatory Approval
On November 2022, the FDA cleared the use of AEYE-DS for the detection of more-than-mild diabetic retinopathy with the Topcon NW400 camera
Indication for Use
The AEYE-DS is indicated for use by health care providers to automatically detect-more-than-mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy.
Accuracy & Usability
In an FDA clinical study for the detection of more-than-mild diabetic retinopathy, the AEYE-DS was found to have 93% sensitivity and over 91.4% specificity using one image per eye captured using the Topcon NW400.
AURORA AEYE
Cost-effective, compact fundus camera with built-in diagnostic screening intelligence
_edited.png)
Compact, cost effective retinal camera with built-in diagnostic screening intelligence
Aurora AEYE is the first portable camera capable of screening for diabetic retinopathy
Ease of use combined with accurate AI make it the first practical screening solution for primary caregivers
NOT SOLD IN THE US
CAUTION: Federal (US) law restricts this device to investigational use only.
See it in Action
